Search for Terms or Answers
Etanercept (Enbrel) received FDA approval Friday for use in children with moderate to severe, chronic plaque psoriasis. Previously approved for adults with plaque psoriasis the new indication will be for chronic plaque psoriasis for those over age 4 years.
Flu season is upon us. While we try our best to vaccinate as many patients as possible, at times it can be challenging for reasons ranging from patient’s perceptions that the vaccine gives them the flu to others stating they are allergic to vaccine components.
The opioid abuse epidemic is well known and the focus of many regulators and health care personnel. The problem also affects the youngest Americans, according to a recent Washington Post article.
The rising incidence of gout has been directly linked to the obesity epidemic. The influence of obesity on gout was further tested in a cohort study of obese patients undergoing bariatric surgery as part of the Swedish Obese Subjects (SOS) study.
Rituximab (RTX) is a monoclonal antibody directed against the CD20 antigen on B cells and when administered causes a marked depletion of CD20+ B cells.
Serum antibodies precede the development of clinical rheumatoid arthritis (RAby) by many years, and yet we still have much to learn about this preclinical phase.
The Wall Street Journal has reported an alarming trend in generic drug pricing that affects many, especially the elderly and those with arthrtis.
The MMWR has reported that Crohn’s disease and ulcerative colitis, collectively known as inflammatory bowel disease (IBD), previously (1999) had an estimated 1.8 million (0.9%) prevalence. But as of 2015, an estimated 3.1 million (1.3%) of U.S.
Dr. Jack Cush reviews highlights, news and journal reports from this week at RheumNow.com
This metanalysis from 2013 reports on an important issue for orthopedists and rheumatologists alike. The issue being in those who need bilateral total knee arthroplasty, is it better to do both knees at once or to do one at a time (staged, serial) arthroplasties..
ClinicalTrials.gov has listed the results of the POSTURE study, a large randomized placebo-controlled trial wherein apremilast was found to yield no benefit (compared to placebo) in treating ankylosing spondylitis (AS) (32.5% vs. 36.6% ASAS20 at week 16) patients.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
